Circulating tumor cells in metastatic breast cancer: clinical relevance and biological potential
Standard
Circulating tumor cells in metastatic breast cancer: clinical relevance and biological potential. / Arkadius, Polasik; Tzschaschel, Marie; Schochter, Fabienne; Friedl, Thomas W. P.; Rack, Brigitte; Hartkopf, Andreas; Fasching, Peter A; Schneeweiss, Andreas; Volkmar, Müller; Jens, Huober; Wolfgang, Janni; Tanja, Fehm.
in: CURR OPIN OBSTET GYN, Jahrgang 31, Nr. 1, 02.2019, S. 76-81.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating tumor cells in metastatic breast cancer: clinical relevance and biological potential
AU - Arkadius, Polasik
AU - Tzschaschel, Marie
AU - Schochter, Fabienne
AU - Friedl, Thomas W. P.
AU - Rack, Brigitte
AU - Hartkopf, Andreas
AU - Fasching, Peter A
AU - Schneeweiss, Andreas
AU - Volkmar, Müller
AU - Jens, Huober
AU - Wolfgang, Janni
AU - Tanja, Fehm
PY - 2019/2
Y1 - 2019/2
N2 - PURPOSE OF REVIEW: The possibility of tumor dissemination through the blood system has been known for years. Circulating tumor cells (CTCs) are detectable in the peripheral blood of patients with early as well as metastatic breast cancer. The prognostic relevance of this biomarker has already been described. By the use of repeated blood sampling along the course of disease, CTCs can be monitored in terms of a regular 'liquid biopsy'. This review aims to summarize recent research findings and actual ongoing clinical studies to demonstrate the actual and future relevance of CTCs in daily clinical routine.RECENT FINDINGS: Recent research results show that additional molecular analysis of CTCs might be helpful in gaining information about tumor characteristics, tumor heterogeneity and possible therapy resistance. Repetitive invasive core biopsies might be avoided.SUMMARY: The assessment of molecular attributes may be indispensable for obtaining an optimized and personalized therapy aiming at extended survival and/or improved quality of life.
AB - PURPOSE OF REVIEW: The possibility of tumor dissemination through the blood system has been known for years. Circulating tumor cells (CTCs) are detectable in the peripheral blood of patients with early as well as metastatic breast cancer. The prognostic relevance of this biomarker has already been described. By the use of repeated blood sampling along the course of disease, CTCs can be monitored in terms of a regular 'liquid biopsy'. This review aims to summarize recent research findings and actual ongoing clinical studies to demonstrate the actual and future relevance of CTCs in daily clinical routine.RECENT FINDINGS: Recent research results show that additional molecular analysis of CTCs might be helpful in gaining information about tumor characteristics, tumor heterogeneity and possible therapy resistance. Repetitive invasive core biopsies might be avoided.SUMMARY: The assessment of molecular attributes may be indispensable for obtaining an optimized and personalized therapy aiming at extended survival and/or improved quality of life.
KW - Biomarkers, Tumor
KW - Breast Neoplasms/immunology
KW - Female
KW - Humans
KW - Male
KW - Neoplasm Metastasis/pathology
KW - Neoplastic Cells, Circulating
KW - Precision Medicine/trends
KW - Prognosis
KW - Quality of Life
U2 - 10.1097/GCO.0000000000000514
DO - 10.1097/GCO.0000000000000514
M3 - SCORING: Review article
C2 - 30540583
VL - 31
SP - 76
EP - 81
JO - CURR OPIN OBSTET GYN
JF - CURR OPIN OBSTET GYN
SN - 1040-872X
IS - 1
ER -
